ADMA Biologics, Inc. (NASDAQ:ADMA) Short Interest Down 6.3% in November

ADMA Biologics, Inc. (NASDAQ:ADMA - Get Free Report) saw a significant decrease in short interest in November. As of November 15th, there was short interest totalling 14,240,000 shares, a decrease of 6.3% from the October 31st total of 15,200,000 shares. Based on an average daily trading volume, of 5,080,000 shares, the days-to-cover ratio is currently 2.8 days.

Insider Buying and Selling at ADMA Biologics

In other ADMA Biologics news, CFO Brad L. Tade sold 15,000 shares of the stock in a transaction that occurred on Friday, November 22nd. The stock was sold at an average price of $21.15, for a total transaction of $317,250.00. Following the transaction, the chief financial officer now owns 199,433 shares in the company, valued at $4,218,007.95. This trade represents a 7.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Lawrence P. Guiheen sold 9,000 shares of ADMA Biologics stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $18.47, for a total value of $166,230.00. Following the completion of the transaction, the director now owns 153,941 shares in the company, valued at $2,843,290.27. The trade was a 5.52 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 3.70% of the company's stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Franklin Resources Inc. grew its holdings in ADMA Biologics by 19.4% during the third quarter. Franklin Resources Inc. now owns 167,644 shares of the biotechnology company's stock worth $3,351,000 after purchasing an additional 27,180 shares during the period. Teachers Retirement System of The State of Kentucky bought a new position in shares of ADMA Biologics during the third quarter worth approximately $1,047,000. Neo Ivy Capital Management acquired a new position in ADMA Biologics in the third quarter valued at about $972,000. Geode Capital Management LLC lifted its holdings in shares of ADMA Biologics by 2.6% during the 3rd quarter. Geode Capital Management LLC now owns 5,381,985 shares of the biotechnology company's stock worth $107,606,000 after acquiring an additional 137,989 shares during the period. Finally, Barclays PLC lifted its stake in ADMA Biologics by 192.2% during the third quarter. Barclays PLC now owns 528,629 shares of the biotechnology company's stock worth $10,567,000 after purchasing an additional 347,692 shares during the last quarter. Institutional investors own 75.68% of the company's stock.

ADMA Biologics Stock Down 2.1 %

ADMA traded down $0.42 on Monday, hitting $19.69. 6,094,748 shares of the company were exchanged, compared to its average volume of 3,633,505. The stock's fifty day moving average is $19.08 and its 200-day moving average is $15.40. ADMA Biologics has a 12 month low of $3.60 and a 12 month high of $23.64. The company has a debt-to-equity ratio of 0.48, a quick ratio of 3.26 and a current ratio of 7.09. The company has a market cap of $4.65 billion, a PE ratio of 71.82 and a beta of 0.64.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last announced its quarterly earnings data on Thursday, November 7th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.13 by $0.02. ADMA Biologics had a return on equity of 53.20% and a net margin of 17.80%. The company had revenue of $119.84 million for the quarter, compared to analysts' expectations of $107.25 million. During the same quarter in the prior year, the business posted $0.01 EPS. Equities research analysts predict that ADMA Biologics will post 0.52 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have recently weighed in on the company. Cantor Fitzgerald restated an "overweight" rating and issued a $20.00 target price on shares of ADMA Biologics in a research note on Friday, September 20th. HC Wainwright lifted their price target on shares of ADMA Biologics from $18.00 to $26.00 and gave the company a "buy" rating in a research note on Friday, November 8th. Finally, Raymond James raised their price target on shares of ADMA Biologics from $18.00 to $25.00 and gave the stock a "strong-buy" rating in a research note on Friday, November 8th.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.